The U.S. Food and Drug Administration (FDA) approved sotatercept in March 2024 for treatment of pulmonary hypertension, ...

Pulmonary hypertension (PH) is a chronic, life-threatening condition involving high blood pressure in the arteries of the lungs. Unlike common hypertension, PH specifically affects the pulmonary ...

Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension ...

WILMINGTON, N.C. (WECT) - Most people are familiar with doctors using a cuff around the wrist to check blood pressure, a practice that can detect systemic hypertension. Dr. Lisa Rose-Jones, with ...

Sotatercept drug may foster lung health in severe pulmonary hypertension patients, controlling pathological spread and ...

Posters presented at the 2023 American Thoracic Society International Conference called for improvements in care for chronic obstructive pulmonary disease (COPD) and pulmonary hypertension. A series ...

Doctors in Germany could have achieved a breakthrough as they treated a young girl suffering from a severe pulmonary condition that can lead to heart failure, by applying umbilical cord stem cell ...

About 1% of the global population has pulmonary hypertension, which currently has no cure. The condition is more common in females, and scientists believe it may be due to the hormone estrogen.

Respira Therapeutics, Inc. (Respira or the "Company"), a Samsara BioCapital portfolio company, today announced that it has ...

Researchers estimate that about 1% of the global population has pulmonary hypertension — a disease caused by high blood pressure in the blood vessels that deliver oxygen to the lungs. Past studies ...